• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Inborn Errors of Metabolism & Screening >Potential Therapeutic Targets of the Endocannabinoid System in Common Neurodegenerative Disorders and Organic Acidemias
【24h】

Potential Therapeutic Targets of the Endocannabinoid System in Common Neurodegenerative Disorders and Organic Acidemias

机译：常见神经退行性疾病和有机酸血症的内源性大麻素系统的潜在治疗靶标

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The cannabinoid chemistry is currently being addressed in preclinical approaches as a viable therapeutic alternative for the management of a wide range of signs, symptoms, and some biochemical hallmarks of many neurological pathologies (such as neuroinflammation and neurodegeneration). This clinical orientation is grounded on the consistent promissory profile that cannabinoid compounds have shown, and the great necessity of feasible options to undergo such disorders. Even though at early research stages, metabolic disorders are starting to rise as potential targets of cannabinoid alternatives; approaches in this term could, in turn, aim to modulate the endocannabinoid response for therapeutic purposes. This review recalls the pathologic scenarios endured in the course of neurological diseases of high occurrence and the most typical metabolic disorders, while discussing the neuroprotective mechanisms of cannabinoid agonists in the central nervous system, and the potential targets of the endocannabinoid system and metabolic disorders.
机译：目前，在临床前方法中已经解决了大麻素化学问题，作为一种可行的治疗选择，可用于管理许多神经病理学（例如神经炎症和神经退行性变）的各种体征，症状和某些生化标志。这种临床取向的基础是大麻素化合物显示出的一致的耐受性，以及进行此类疾病的可行选择的极大必要性。即使在早期研究阶段，新陈代谢紊乱也开始上升，成为大麻素替代品的潜在目标。该术语中的方法反过来可以旨在调节内源性大麻素反应以达到治疗目的。这篇综述回顾了在高发生率的神经疾病和最典型的代谢性疾病过程中所遭受的病理情况，同时讨论了中枢神经系统中大麻素激动剂的神经保护机制，以及内源性大麻素系统和代谢性疾病的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号